Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.
Völkel S, Tarawneh TS, Sacher L, Bhagwat AM, Karim I, Mack HID, Wiesmann T, Beutel B, Hoyer J, Keller C, Renz H, Burchert A, Neubauer A, Graumann J, Skevaki C, Mack EKM.
Völkel S, et al. Among authors: wiesmann t.
Front Med (Lausanne). 2023 May 24;10:1176427. doi: 10.3389/fmed.2023.1176427. eCollection 2023.
Front Med (Lausanne). 2023.
PMID: 37293294
Free PMC article.